Rena Buckstein
YOU?
Author Swipe
View article: Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti–HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti–HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial Open
Background and Aims: Immunosuppression can cause hepatitis B virus (HBV) reactivation, leading to severe outcomes in patients with “resolved” HBV infection. This multicenter, randomized, placebo-controlled trial assessed the efficacy of pr…
View article: Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?
Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes? Open
Not available.
View article: Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies Open
Summary DNA methyltransferase inhibitors (DNMTis) are commonly used in treating chronic myelomonocytic leukaemia (CMML); however, data from prospective studies of DNMTis in CMML are limited. The present analysis evaluated the efficacy, saf…
View article: Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement Open
Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to in…
View article: Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms Open
Context.— Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.— To propose a standardized approach to MDS evaluation in…
View article: A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML Open
What is this summary about? This summary describes results from a phase 3 clinical trial called ASCERTAIN.Researchers compared two treatments in people with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML), either …
View article: Advancing drug development in myelodysplastic syndromes
Advancing drug development in myelodysplastic syndromes Open
Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by t…
View article: Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores
Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores Open
Introduction: Myelodysplastic syndromes (MDS) are a genetically/mutationally heterogenous group of myeloid cancers associated with bone marrow failure/cytopenias and with a predisposition towards progression to acute myeloid leukemia (AML)…
View article: Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes Open
Introduction: Limited treatment options are available for patients with red blood cell (RBC) transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). Imetelstat (IME), a first-in-class, direct, and competitive inhibitor of…
View article: Reducing unnecessary outpatient group and screen testing at a regional cancer center
Reducing unnecessary outpatient group and screen testing at a regional cancer center Open
Background Unnecessary group and screens (G&S) can lead to unnecessary antibody investigations, use of technologist time, and laboratory resources. Local Problem A baseline audit at our institution identified that 25% of G&S from the cance…
View article: Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario
Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario Open
Acute leukemia is a rapidly progressive cancer of the blood and bone marrow that requires a high degree of complex, specialized, resource-intensive clinical and supportive care. The aging Canadian population has introduced an unprecedented…
View article: Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada
Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada Open
Management of anemia and/or transfusion dependence (TD) after failure of erythropoietic-stimulating agents (ESA) and therapeutic options after hypomethylating agent (HMA) failures remain the biggest challenges for physicians treating lower…
View article: Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) Open
Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the prom…
View article: Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies Open
The associations between RBC transfusion dependence (TD) in patients with myelodysplastic syndromes (MDS) and lower survival, quality of life (QOL), iron overload and cardiac morbidity were recently summarized in a systematic review.1 Howe…
View article: A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML Open
Although induction chemotherapy (IC) is the standard of care in medically fit patients with newly diagnosed acute myeloid leukemia (AML), limited retrospective data indicate that patients at adverse-risk may benefit from azacytidine and ve…
View article: The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy
The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy Open
Background: CHIP is more commonly encountered in cancer patients, such as those with lymphoma, than in the general population likely attributable to age, cancer risk factors and treatment. While the adverse health associations with clonal …
View article: Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment
Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment Open
Background: Acute myeloid leukemia with myelodysplasia related changes (AML-MRC) a distinct clinico-pathologic subtype of AML recognized in the WHO and ICC 2022 classifications of hematolymphoid neoplasms (AML-MRC and AML-MR respectively).…
View article: Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia
Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia Open
Background: Despite the rapid onset and life-threatening nature of acute leukemia (AL) and its treatment, there is a lack of research on its psychological and physical consequences and even less on interventions to alleviate them [Bryant 2…
View article: S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS) Open
Topic: 10. Myelodysplastic syndromes - Clinical Background: In 2022 two new classifications for myeloid neoplasms were published: the World Health Organization (WHO) and International Consensus Classification (ICC). Aims: To validate and c…
View article: P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA
P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA Open
Background: Induction chemotherapy (IC) for acute myeloid leukemia (AML) is intensive and carries a significant risk of morbidity and mortality. In the absence of allogenic bone marrow transplant (AlloBMT), relapse is common and survival i…
View article: P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by persistent monocytosis, splenomegaly, and both dysplastic and myeloprolifera…
View article: Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes Open
PURPOSE: The role of frailty in affecting survival in myelodysplastic syndromes (MDS) is increasingly recognized. Despite this, a paucity of data exists on the association between frailty and other clinically meaningful outcomes including …
View article: Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes Open
Myelodysplastic syndromes/neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clini…